CRISPR Therapeutics AG(CRSP)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
CRSP | 5.46 B | -12.15x | 10.41% | - | $-4.65 | -26.10% | 0.45 | - | $78.48 | $44.12 |
688235.SS | 31.18 B | 93.77x | 29.60% | 10.70% | $2.89 | 14.66% | 0.40 | - | $346.00 | $205.51 |
IDIA.SW | 1.35 B | -3.70x | -26.80% | -1.58% | $-1.38 | - | - | - | $7.56 | $2.62 |
MLTX | 1.29 B | -3.94x | - | - | $-3.86 | -67.48% | 0.24 | - | $62.75 | $5.95 |
KURN.SW | 716.1 M | 100.28x | 45.50% | 5.13% | $0.18 | - | - | - | $34.20 | $17.69 |
Peer Valuation & Performance Analysis
Peer group analysis for CRISPR Therapeutics AG (CRSP) compared to its primary competitors (including 688235.SS, IDIA.SW, MLTX) reveals distinct metrics. CRSP trades at a valuation discount relative to its competitors, with a P/E ratio of -12.1x versus the peer average of 46.6x (representing a 126% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, CRSP's revenue growth of 10.4% lags behind the peer average of 16.1%, indicating potential market share losses or slower industry adoption.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• CRSP ranks #0 in P/E ratio, #3 in revenue growth, and #3 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $57.50 | $57.80 | $55.72 | $56.49 | 1,487,700 | -1.76% |
| 2026-09-02 | $57.13 | $58.96 | $55.59 | $56.92 | 910,700 | -0.37% |
| 2026-09-01 | $56.22 | $57.13 | $55.43 | $56.82 | 890,500 | +1.07% |
| 2026-08-31 | $56.55 | $57.49 | $56.20 | $56.98 | 1,390,800 | +0.76% |
| 2026-08-28 | $58.22 | $59.37 | $57.10 | $57.72 | 1,386,300 | -0.86% |
| 2026-08-27 | $59.12 | $60.11 | $58.02 | $59.37 | 1,186,900 | +0.42% |
| 2026-08-26 | $60.18 | $60.39 | $58.06 | $59.23 | 953,400 | -1.58% |
| 2026-08-25 | $57.93 | $61.55 | $57.51 | $60.90 | 2,080,800 | +5.13% |
| 2026-08-24 | $58.75 | $58.96 | $56.62 | $57.08 | 1,118,600 | -2.85% |
| 2026-08-21 | $59.72 | $62.53 | $58.89 | $59.50 | 2,450,600 | -0.37% |
| 2026-08-20 | $58.73 | $60.90 | $56.94 | $58.12 | 2,910,400 | -1.04% |
| 2026-08-19 | $55.00 | $59.91 | $54.98 | $59.81 | 3,833,900 | +8.75% |
| 2026-08-18 | $53.20 | $53.88 | $51.80 | $52.97 | 1,313,800 | -0.43% |
| 2026-08-17 | $53.08 | $54.57 | $52.61 | $54.28 | 958,200 | +2.26% |
| 2026-08-14 | $53.99 | $54.00 | $52.23 | $53.55 | 807,600 | -0.81% |
Explore More Analysis for CRSP
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.